These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 23659299)

  • 21. Meningococcal Antigen Typing System Development and Application to the Evaluation of Effectiveness of Meningococcal B Vaccine and Possible Use for Other Purposes.
    Domnich A; Gasparini R; Amicizia D; Boccadifuoco G; Giuliani MM; Panatto D
    J Immunol Res; 2015; 2015():353461. PubMed ID: 26351645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.
    Mameli C; Galli E; Mantegazza C; Fabiano V; Zuccotti GV
    Future Microbiol; 2015; 10(10):1579-98. PubMed ID: 26437903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region.
    Soriano-Gabarró M; Wolter J; Hogea C; Vyse A
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):761-74. PubMed ID: 21905785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New frontiers in meningococcal vaccines.
    Anderson AS; Jansen KU; Eiden J
    Expert Rev Vaccines; 2011 May; 10(5):617-34. PubMed ID: 21604983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on the use of meningococcal serogroup C CRM₁₉₇-conjugate vaccine (Meningitec) against meningitis.
    Badahdah AM; Rashid H; Khatami A
    Expert Rev Vaccines; 2016; 15(1):9-29. PubMed ID: 26560735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Neisseria meningitidis: new vaccines and preventive strategies].
    Morciano L; Zaratti L; Franco E
    Ig Sanita Pubbl; 2012; 68(1):97-104. PubMed ID: 22507995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Active immunization against serogroup B Neisseria meningitidis].
    Navarro-Alonso JA
    Enferm Infecc Microbiol Clin; 2003 Nov; 21(9):513-9. PubMed ID: 14572386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of vaccination during an epidemic of serogroup C meningococcal disease in Salvador, Brazil.
    Cardoso CW; Pinto LL; Reis MG; Flannery B; Reis JN
    Vaccine; 2012 Aug; 30(37):5541-6. PubMed ID: 22749604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Paediatric meningococcal meningitis in France: ACTIV/GPIP network results].
    Levy C; Taha MK; Bingen E; Cohen R;
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S49-54. PubMed ID: 22883366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A combined approach to assess the potential coverage of a multicomponent protein-based vaccine.
    Boccadifuoco G; Brunelli B; Pizza MG; Giuliani MM
    J Prev Med Hyg; 2012 Jun; 53(2):56-60. PubMed ID: 23240161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.
    Perez JL; Absalon J; Beeslaar J; Balmer P; Jansen KU; Jones TR; Harris S; York LJ; Jiang Q; Radley D; Anderson AS; Crowther G; Eiden JJ
    Expert Rev Vaccines; 2018 Jun; 17(6):461-477. PubMed ID: 29883226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eliminating Meningococcal Epidemics From the African Meningitis Belt: The Case for Advanced Prevention and Control Using Next-Generation Meningococcal Conjugate Vaccines.
    Alderson MR; LaForce FM; Sobanjo-Ter Meulen A; Hwang A; Preziosi MP; Klugman KP
    J Infect Dis; 2019 Oct; 220(220 Suppl 4):S274-S278. PubMed ID: 31671447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention.
    Esposito S; Castellazzi L; Bosco A; Musio A; Stoddard J
    Immunotherapy; 2014; 6(4):395-408. PubMed ID: 24815780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances with vaccination against Neisseria meningitidis.
    Borrow R
    Trop Med Int Health; 2012 Dec; 17(12):1478-91. PubMed ID: 22947250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.
    Zlotnick GW; Jones TR; Liberator P; Hao L; Harris S; McNeil LK; Zhu D; Perez J; Eiden J; Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2015; 11(1):5-13. PubMed ID: 25483509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa.
    Okoko BJ; Idoko OT; Adegbola RA
    Vaccine; 2009 Mar; 27(14):2023-9. PubMed ID: 19095025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of meningococcal serogroup C vaccine programmes.
    Borrow R; Abad R; Trotter C; van der Klis FR; Vazquez JA
    Vaccine; 2013 Sep; 31(41):4477-86. PubMed ID: 23933336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps.
    LaForce FM; Djingarey M; Viviani S; Preziosi MP
    Hum Vaccin Immunother; 2018 May; 14(5):1098-1102. PubMed ID: 28968148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Vaccinal strategies in response to new epidemiological challenges in 2010. Reasonable hope for a "B" meningococcal vaccine].
    Nicolas P
    Med Trop (Mars); 2010 Aug; 70(4):325-32. PubMed ID: 22368926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.